Business Wire

MA-TA/PRIORITY-SOFTWARE

5.10.2020 06:02:13 CEST | Business Wire | Press release

Share
TA Associates Completes Significant Growth Investment in Priority Software

TA Associates, a leading global growth private equity firm, today announced that it has completed a significant growth investment in Priority Software Ltd., a leading global provider of Enterprise Resource Planning (ERP) software. TA joins existing investor Fortissimo Capital, a leading private equity firm based in Israel and focused on special situations and growth opportunities, as an institutional investor in Priority Software. Financial terms of the transaction were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201004005040/en/

Founded in 1986, Priority Software provides end-to-end cloud-based (SaaS) and on-premise business management solutions for organizations of all sizes to improve business efficiency and the customer experience. The company’s Priority PRO product provides comprehensive ERP software for medium to large organizations encompassing demand planning, manufacturing operations, financial management, human capital management, procurement and supply chain management. Priority Software also provides business management software for smaller companies that focuses on financial management, reporting and accounting. The company has more than 10,000 customers and over 300,000 end users across multiple end markets, including manufacturing, construction, healthcare and pharma, services, and retail and wholesale. Priority Software has more than 200 employees located across five offices in Israel, the U.S., the UK and Belgium.

“TA’s extensive experience investing in the enterprise software space and in partnering with growing companies like Priority Software made the firm an attractive investment partner,” said Andres Richter, CEO of Priority Software. “We’ve identified opportunities to accelerate our growth and further expand Priority Software’s market penetration both nationally and internationally, and we believe that TA will be a valuable partner for us alongside Fortissimo to help us realize our ambitions.”

“Priority Software is considered by many to be a market leader in the Israeli ERP space, and we believe that the company has significant untapped potential,” said Stefan Dandl, a Senior Vice President at TA Associates who has joined the Priority Software Board of Directors. “Additionally, there is significant opportunity for Priority Software to expand internationally in its addressable market through acquisitive and organic growth. We look forward to partnering with the Priority Software and Fortissimo teams in these growth efforts.”

“We have been following Priority Software for several years and have been impressed by the quality of the company’s management team and the growth they have achieved to date,” said Naveen Wadhera, a Managing Director and Co-head of the EMEA Technology Group at TA Associates who has joined the Priority Software Board of Directors. “The ERP market continues to see strong growth globally, driven by a need for operational efficiency and transparency, coupled with increasing adoption of cloud-based solutions. We believe that Priority Software’s flexible, innovative and high-quality products make it well-positioned to capitalize on these opportunities, and we are pleased to become an investment partner alongside Fortissimo as the company enters its next stage of growth.”

“As a firm focused on creating value from growth, Fortissimo is proud to have partnered with the Priority Software team and been a part of the company’s rapid growth over the last six years,” said Yuval Cohen, Managing Partner at Fortissimo Capital. “We continue to believe in Priority Software’s growth potential in Israel as a result of its leadership position, loyal customer base and superior technology and its potential to continue driving growth worldwide. We are excited to welcome TA as a new partner to further accelerate Priority Software’s growth.”

About Priority Software

Priority Software provides flexible, end-to-end business management solutions for organizations of all sizes in a wide range of industries, from a fully featured ERP platform serving multinational corporations, to small and growing businesses. Recognized by top industry analysts and professionals for its product innovation, Priority Software improves business efficiency and the customer experience, providing real-time access to business data and insights in the cloud, on premise and on-the-go. With offices in the U.S., the UK, Belgium and Israel, and a global network of business partners, Priority Software enables more than 10,000 companies in 40 countries to manage and grow their business. For more information, visit www.priority-software.com .

About TA Associates

TA Associates is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 500 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $33.5 billion in capital since its founding in 1968 and is committing to new investments at the pace of over $2 billion per year. The firm’s more than 90 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA Associates can be found at www.ta.com .

About Fortissimo Capital

Fortissimo Capital is a private equity fund, established in 2004, that invests primarily in Israeli-related technology and industrial companies to expedite growth. Fortissimo raised $1.6 billion across five funds. Fortissimo Capital is a special situations and growth capital Israeli-related private equity fund focused primarily on maturing technology and industrial companies that are at a point of inflection. Fortissimo's investment strategy is to achieve capital appreciation through taking a leading role and active approach in Israeli-related global businesses that require immediate and significant change, or stimulation of growth and by building business fundamentals to facilitate sustainable long-term growth and value creation. More information about Fortissimo Capital is available at www.ffcapital.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye